Our R&D Approach

Our research mission is simple: innovations that improve the quality of life of people everywhere. That motivation keeps us at the forefront of the Healthcare, Life Science and Electronics industries.

Healthcare R&D

Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis to infertility. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more

Life Science R&D

R&D focus: Reimagining new ways to meet the needs of our customers

Innovation is at the core of the value that we deliver to our customers. Our Life Science business is research driven and innovation focused. In 2016, we invested 260 million Euro in R&D which supported our innovation in launching 2,100 products – products designed to meet our customers' most unmet needs – from antibodies to water purification systems.

The ability to innovate is the core of our culture across all three of our businesses; Research Solutions, Process Solutions and Applied Solutions. Learn more

Performance Materials R&D

R&D focus: Keeping the world’s Electronics on the cutting edge

Our Electronics business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more

Related News

View All News
  1. Information

    Merck KGaA, Darmstadt, Germany, and TU Darmstadt Extend Strategic Research ...

    Merck KGaA, Darmstadt, Germany, has extended its existing strategic joint research collaboration with the Technical University of Darmstadt, Darmstadt, Germany, by another five years.

    2021/04/14

  2. Press Releases

    Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as ...

    Merck KGaA, Darmstadt, Germany, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment.

    2021/03/16

  3. Press Releases

    Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer ...

    Merck KGaA, Darmstadt, Germany today announced a worldwide in-licensing agreement with Debiopharm, Lausanne, Switzerland, for the development and commercialization of xevinapant (Debio 1143).

    2021/03/01

Healthcare R&D

Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis and infertility to colds and pains. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more